abacavir/lamivudine lupin 600/300 abacavir (as hydrochloride) 600 mg and lamivudine 300 mg film-coated tablet blister pack
lupin australia pty limited - lamivudine, quantity: 300 mg; abacavir hydrochloride monohydrate, quantity: 714.162 mg (equivalent: abacavir, qty 600 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; crospovidone; povidone; magnesium stearate; ferric oxide; titanium dioxide; hypromellose; sunset yellow fcf; polysorbate 80; macrogol 400 - abacavir/lamivudine lupin is a combination of two nucleoside analogues (abacavir and lamivudine). abacavir/lamivudine lupin is indicated in antiretroviral combination therapy for the treatment of human immunodeficiency virus (hiv) infection in adults and adolescents from 12 years of age.
epzicom- abacavir sulfate and lamivudine tablet, film coated
a-s medication solutions - abacavir sulfate (unii: j220t4j9q2) (abacavir - unii:wr2tip26vs), lamivudine (unii: 2t8q726o95) (lamivudine - unii:2t8q726o95) - abacavir 600 mg - epzicom, in combination with other antiretroviral agents, is indicated for the treatment of human immunodeficiency virus type 1 (hiv‑1) infection. epzicom is contraindicated in patients: pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to epzicom during pregnancy. healthcare providers are encouraged to register patients by calling the antiretroviral pregnancy registry (apr) at 1-800-258-4263. risk summary available data from the apr show no difference in the overall risk of birth defects for abacavir or lamivudine compared with the background rate for birth defects of 2.7% in the metropolitan atlanta congenital defects program (macdp) reference population [see data] . the apr uses the macdp as the u.s. reference population for birth defects in the general population. the macdp evaluates women and infants from a limited geographic area and does not include outcomes for births that occurred at less than 20 weeks gestation. the rate of miscarria
apo-abacavir tablet
apotex inc - abacavir (abacavir sulfate) - tablet - 300mg - abacavir (abacavir sulfate) 300mg - nucleoside and nucleotide reverse transcriptase inhibitors
mint-abacavir tablet
mint pharmaceuticals inc - abacavir (abacavir sulfate) - tablet - 300mg - abacavir (abacavir sulfate) 300mg - nucleoside and nucleotide reverse transcriptase inhibitors
abacavir tablet
remedyrepack inc. - abacavir sulfate (unii: j220t4j9q2) (abacavir - unii:wr2tip26vs) - abacavir 300 mg
abacavir tablet film coated
avera mckennan hospital - abacavir sulfate (unii: j220t4j9q2) (abacavir - unii:wr2tip26vs) - abacavir 300 mg
abacavir sulfate tablet film coated
avera mckennan hospital - abacavir sulfate (unii: j220t4j9q2) (abacavir - unii:wr2tip26vs) - abacavir 300 mg
triumeq- abacavir sulfate, dolutegravir sodium, lamivudine tablet, film coated triumeq pd- abacavir sulfate, dolutegravir sodiu
viiv healthcare company - abacavir sulfate (unii: j220t4j9q2) (abacavir - unii:wr2tip26vs), dolutegravir sodium (unii: 1q1v9v5wyq) (dolutegravir - unii:dko1w9h7m1), lamivudine (unii: 2t8q726o95) (lamivudine - unii:2t8q726o95) - abacavir 600 mg - triumeq and triumeq pd are indicated for the treatment of hiv-1 infection in adults and in pediatric patients aged at least 3 months and weighing at least 6 kg. limitations of use: triumeq and triumeq pd alone are not recommended in patients with resistance‑associated integrase substitutions or clinically suspected integrase strand transfer inhibitor (insti) resistance because the dose of dolutegravir in triumeq and triumeq pd is insufficient in these subpopulations. see full prescribing information for tivicay (dolutegravir). triumeq and triumeq pd are contraindicated in patients: pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in individuals exposed to triumeq during pregnancy. healthcare providers are encouraged to register patients by calling the antiretroviral pregnancy registry (apr) at 1‑800‑258‑4263. risk summary data from an ongoing birth outcome surveillance study has identified an increased risk of neural tube defects when dolutegravir, a componen
abacavir sulfate and lamivudine tablets for oral tablet for oral suspension
abacavir sulfate and lamivudine tablets for oral - tablet for oral suspension - abacavir sulfate usp equivalent to abacavir - lamivudine and abacavir
apo-abacavir-lamivudine-zidovudine tablet
apotex inc - abacavir (abacavir sulfate); lamivudine; zidovudine - tablet - 300mg; 150mg; 300mg - abacavir (abacavir sulfate) 300mg; lamivudine 150mg; zidovudine 300mg - nucleoside and nucleotide reverse transcriptase inhibitors